RFK Jr. Under Fire: Fact-Check Reveals Misleading Claims on COVID-19 Vaccine Access Amid New FDA Guidance

U.S. Health Secretary Robert F. Kennedy Jr. is facing intense scrutiny following his September 4 testimony before the Senate Finance Committee, where he controversially stated that “everybody can get” the COVID-19 vaccine. This assertion directly contradicts new guidance issued by the U.S. Food and Drug Administration (FDA) on August 27, which significantly limits eligibility for the updated shot.

During the contentious hearing, senators, including Elizabeth Warren (D-Mass.), criticized Kennedy for restricting vaccine access, pointing to his prior promise not to “take away anybody’s vaccines.” The FDA’s revised guidelines approve the vaccine primarily for individuals aged 65 and older, and those 6 months and older with underlying health conditions that elevate their risk of severe COVID-19 infection.

A fact-check of Kennedy’s blanket statement reveals it to be misleading and premature. Healthy individuals under 65 who wish to receive the vaccine may now encounter substantial barriers, including the potential need for a doctor’s prescription and significant out-of-pocket costs. Insurance coverage and over-the-counter pharmacy availability are largely contingent on upcoming recommendations from the Centers for Disease Control and Prevention (CDC).

Further complicating the landscape are recent shake-ups within the CDC. Kennedy reportedly fired all 17 members of the CDC’s immunization advisory committee on June 9, replacing some with individuals known for anti-vaccine views. Additionally, CDC Director Susan Monarez was dismissed on August 27, allegedly over disputes regarding vaccine policy. The newly constituted advisory panel is slated to meet on September 18-19, with their guidance expected to critically influence insurance coverage and nationwide access.

As of September 4, pharmacy scheduling applications in some areas were already reflecting state restrictions or inventory limitations. While doctors can still prescribe the vaccine “off-label” for those outside FDA-approved categories, this process introduces additional costs and logistical hurdles. The previous ease of accessing COVID-19 vaccines at local pharmacies, often at minimal to no cost, is no longer guaranteed for the 2025-26 season, rendering Kennedy’s broad assurance largely inaccurate.

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.